Reducing medical support is a clinically relevant outcome, but its interpretation depends on the rules used to adjust that support and the care given to every group. Primary study
What was reported
Forty-one adults dependent on parenteral nutrition underwent dietary optimization and were randomized to glutamine, growth hormone, or their combination with corresponding placebos. Both GH-containing approaches initially allowed greater support reduction than glutamine plus diet. At three-month follow-up, only the GH–glutamine combination retained a significant advantage over that comparator. Primary report
Our appraisal: the background care is part of the evidence
This was not a comparison of an isolated drug against unchanged routine behavior. Dietary optimization and structured monitoring were built into the design. Removing that context would misrepresent what was tested.
Parenteral nutrition was adjusted through clinical criteria. Consistency in those decisions is important because the endpoint partly reflects how support was managed. Blinding and explicit adjustment rules help distinguish a treatment effect from differences in clinical decision-making.
Reduced volume, calories, and infusion frequency are not necessarily equivalent to complete independence from support. A summary should name the measured reduction rather than implying that every participant stopped parenteral nutrition.
The follow-up finding also changes the conclusion. An initial advantage that is not retained after treatment ends should not be described as durable. Conversely, the combination's retained advantage does not isolate glutamine's contribution without the appropriate direct comparison and uncertainty.
The trial supports a specific combination-and-care strategy in selected patients. It does not establish general gut regeneration, replacement of nutritional monitoring, or the same outcome for another GH-related peptide.
Frequently asked questions
How many adults were randomized?
Forty-one.
Was diet optimized?
Yes.
Did both GH-containing groups initially reduce support more?
Yes, relative to the reported comparator.
Which retained a significant follow-up advantage?
The GH–glutamine combination.
Does reduction mean everyone became support-independent?
No.
Is the background care optional to the interpretation?
No.
Does this establish the same effect for other peptides?
No.